| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 754 | 831 | 871 | 823 | 819 | 1,299 | 795 | 803 | 707 | 888 | 834 | 785 | 764 | 964 | 838 | 2,132 | 776 | 939 | 826 | 826 | 815 | 985 | 833 | 962 | 850 | 1,050 | 985 |
| Expenses | 608 | 663 | 688 | 588 | 623 | 688 | 1,408 | 602 | 535 | 739 | 611 | 707 | 586 | 678 | 636 | 634 | 596 | 660 | 585 | 618 | 618 | 668 | 751 | 673 | 584 | 689 | 658 |
| EBITDA | 145 | 168 | 183 | 236 | 196 | 611 | -613 | 201 | 172 | 150 | 223 | 78 | 178 | 286 | 202 | 1,497 | 180 | 279 | 241 | 208 | 198 | 318 | 83 | 290 | 266 | 361 | 327 |
| Operating Profit % | 17 % | 19 % | 17 % | 22 % | 21 % | 22 % | -81 % | 22 % | 18 % | 16 % | 23 % | 5 % | 18 % | 27 % | 22 % | 22 % | 20 % | 28 % | 27 % | 22 % | 19 % | 30 % | 7 % | 28 % | 28 % | 32 % | 31 % |
| Depreciation | 11 | 12 | 12 | 14 | 19 | 23 | 18 | 23 | 22 | 22 | 18 | 18 | 18 | 17 | 18 | 15 | 16 | 16 | 16 | 17 | 16 | 18 | 17 | 18 | 16 | 17 | 19 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Profit Before Tax | 134 | 157 | 171 | 222 | 176 | 587 | -634 | 177 | 149 | 127 | 204 | 60 | 160 | 268 | 184 | 1,482 | 163 | 262 | 224 | 190 | 181 | 299 | 65 | 271 | 249 | 344 | 308 |
| Tax | 50 | 56 | 57 | 75 | 63 | 85 | 27 | 39 | 38 | 51 | 48 | 45 | 39 | 64 | 34 | 263 | 44 | 69 | 60 | 57 | 49 | 82 | 20 | 76 | 67 | 91 | 78 |
| Net Profit | 84 | 101 | 114 | 147 | 114 | 503 | -661 | 138 | 111 | 77 | 157 | 14 | 121 | 204 | 150 | 1,219 | 119 | 193 | 165 | 133 | 132 | 218 | 46 | 195 | 182 | 253 | 230 |
| EPS in ₹ | 9.93 | 5.95 | 6.71 | 8.67 | 6.70 | 29.68 | -39.03 | 8.15 | 6.54 | 4.51 | 10.26 | 0.85 | 7.14 | 12.06 | 8.87 | 71.96 | 7.04 | 11.42 | 9.71 | 7.41 | 7.04 | 12.84 | 9.89 | 11.37 | 10.76 | 14.67 | 13.57 |
GlaxoSmithKline Pharmaceuticals
2,657.80
-25.30
(-0.94%)
Market Cap
45,024.74 Cr
EPS
34.83
PE Ratio
53.20
Dividend Yield
1.19 %
Industry
Healthcare52 Week High
3,088.00
52 Week low
1,842.05
PB Ratio
27.17
Debt to Equity
0.01
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
| 1,683.45 | 4,03,916.05 | 34.10 | 49,887.20 | 12.06 | 9,648 | 13.77 | 52.67 | |
| 5,620.45 | 1,49,205.29 | 72.77 | 8,184.00 | 0.89 | 1,600 | 64.53 | 45.57 | |
| 1,461.90 | 1,18,065.10 | 23.53 | 26,520.70 | 14.17 | 4,155 | 47.38 | 52.92 | |
| 3,056.05 | 1,03,430.62 | 56.27 | 10,785.70 | 11.59 | 1,656 | 13.54 | 47.23 | |
| 1,107.95 | 92,448.55 | 17.17 | 28,905.40 | 12.36 | 5,578 | 1.69 | 30.37 | |
| 2,201.15 | 90,812.16 | 43.84 | 10,615.60 | 19.57 | 1,942 | -16.38 | 35.15 | |
| 1,968.45 | 89,800.21 | 31.28 | 20,141.50 | 19.94 | 1,936 | 38.82 | 43.62 | |
| 883.10 | 88,860.52 | 19.73 | 19,831.50 | 13.82 | 3,831 | 29.92 | 40.81 | |
| 1,094.75 | 63,583.26 | 18.24 | 29,559.20 | 17.55 | 3,169 | -10.04 | 43.94 | |
| 29,597.00 | 62,891.56 | 47.49 | 6,097.20 | 10.80 | 1,201 | 16.01 | 49.75 |
Growth Rate
Revenue Growth
6.68 %
Net Income Growth
-2.90 %
Cash Flow Change
20.19 %
ROE
-4.90 %
ROCE
-3.94 %
EBITDA Margin (Avg.)
6.85 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 3,216 | 3,055 | 3,004 | 3,948 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 |
| Fixed Assets | 123 | 210 | 258 | 325 | 432 | 758 | 387 | 331 | 330 | 321 |
| Current Assets | 2,587 | 2,174 | 1,674 | 2,186 | 2,010 | 1,775 | 2,203 | 3,708 | 2,494 | 2,798 |
| Capital Work in Progress | 115 | 268 | 606 | 923 | 1,003 | 120 | 13 | 31 | 20 | 14 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 366 | 518 | 813 |
| Other Assets | 2,977 | 2,577 | 2,140 | 2,700 | 2,477 | 2,257 | 2,715 | 3,907 | 2,458 | 2,408 |
| Total Liabilities | 3,216 | 3,055 | 3,004 | 3,948 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 |
| Current Liabilities | 1,107 | 579 | 720 | 1,600 | 1,454 | 1,024 | 1,355 | 1,698 | 1,326 | 1,525 |
| Non Current Liabilities | 280 | 292 | 277 | 290 | 317 | 291 | 282 | 272 | 259 | 254 |
| Total Equity | 1,829 | 2,183 | 2,007 | 2,057 | 2,140 | 1,821 | 1,478 | 2,663 | 1,741 | 1,778 |
| Reserve & Surplus | 1,744 | 2,099 | 1,922 | 1,973 | 1,970 | 1,651 | 1,309 | 2,494 | 1,572 | 1,608 |
| Share Capital | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 | 169 | 169 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 21 | -0 | 24 | 62 | -102 | 6 | 300 | -119 | -251 | 29 |
| Investing Activities | 180 | 499 | 301 | -104 | -153 | -57 | 418 | -406 | 808 | 9 |
| Operating Activities | 338 | 139 | 234 | 473 | 410 | 491 | 578 | 811 | 484 | 582 |
| Financing Activities | -497 | -638 | -511 | -307 | -358 | -428 | -696 | -524 | -1,543 | -562 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 3.48 % | 4.02 % | 4.36 % | 4.50 % |
| DIIs | 5.31 % | 5.51 % | 5.50 % | 5.61 % | 5.61 % | 4.08 % | 10.45 % | 10.28 % | 10.30 % | 10.23 % | 10.01 % | 8.53 % | 7.90 % | 7.50 % | 7.34 % | 7.30 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 11.02 % | 10.86 % | 10.83 % | 10.67 % | 10.41 % | 10.41 % | 10.40 % | 10.56 % | 10.54 % | 10.57 % | 10.62 % | 11.08 % | 11.27 % | 11.15 % | 10.97 % | 10.96 % |
| Others | 8.67 % | 8.62 % | 8.67 % | 8.73 % | 8.98 % | 10.51 % | 4.15 % | 4.16 % | 4.16 % | 4.20 % | 4.37 % | 5.38 % | 2.35 % | 2.33 % | 2.33 % | 2.23 % |
| No of Share Holders | 1,19,951 | 1,20,476 | 1,21,445 | 1,23,480 | 1,10,141 | 1,12,964 | 1,16,651 | 1,20,127 | 1,20,415 | 1,19,032 | 1,15,266 | 1,14,663 | 1,18,994 | 1,18,515 | 1,19,228 | 1,19,625 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 30 | 35 | 20 | 40 | 30 | 90 | 32 | 32 | 0.00 |
| Dividend Yield (%) | 0.00 | 2.87 | 2.7 | 1.59 | 2.78 | 1.8 | 7.05 | 1.64 | 1.19 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Announcement under Regulation 30 (LODR)-Change in Management
Disclosure Under Regulation 30
Disclosure Under Regulation 30
Disclosure Under Regulation 30
Disclosure Under Regulation 30
Rumour verification - Regulation 30(11)
Rumour verification - Regulation 30(11)
Rumour verification - Regulation 30(11)
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Meeting Updates
Integrated Filing (Financial)
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Change in Management
Ouctome
Board Meeting Outcome for Outcome
Rumour verification - Regulation 30(11)
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Disclosure Under Regulation 30
Rumour verification - Regulation 30(11)
Disclosure Under Regulation 30
Disclosure Under Regulation 30
Disclosure Under Regulation 30
Rumour verification - Regulation 30(11)
Closure of Trading Window
Board Meeting Intimation for Un-Audited Financial Results For The Third Quarter & Nine Months Ended 31St December 2024.
Board Meeting Intimation for Un Audited Financial Results For Quarter And Nine Months Ended 31St December 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Disclosure under Regulation 30A of LODR
Announcement under Regulation 30 (LODR)-Change in Management
Announcement under Regulation 30 (LODR)-Change in Management
Intimation Under Regulation 30
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Announcement Under Regulation 30: Updates
Corporate Action- Record Date For Special Interim Dividend
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Outcome Of Meeting
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Dividend Updates
Corporate Action-Board approves Dividend
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Un Audited Financials Results For Quarter & Half Year Ended 30Th September 2024
Board Meeting Outcome for Outcome Of Board
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Record Date
Technical Indicators
RSI(14)
Neutral 63.83
ATR(14)
Less Volatile 121.36
STOCH(9,6)
Neutral 74.25
STOCH RSI(14)
Neutral 33.97
MACD(12,26)
Bullish 4.56
ADX(14)
Strong Trend 42.75
UO(9)
Bearish 47.50
ROC(12)
Uptrend And Accelerating 6.95
WillR(14)
Neutral -28.20
About GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals Limited is an Indian subsidiary of UK-based GSK Plc, engaged in manufacturing, distributing, and trading pharmaceuticals. The company operates in three main product areas: vaccines, specialty medicines, and general medicines. It has manufacturing facilities in Nashik and Thane, with a clinical development center in Bangalore. The company's portfolio includes medicines for various therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. They also offer a range of vaccines for various diseases. Key brands include Augmentin, Calpol, Shingrix, Nucala, and Trelegy Ellipta. The company has six branch offices and works with 22 contract manufacturing organizations across India. A new manufacturing facility is being developed in Vemgal, Karnataka, with an investment of over Rs 1000 crore.
Website
Chairperson NameRenu S Karnad
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
